Amylyx Pharmaceuticals

Yahoo Finance • 22 days ago

Amylyx Pharmaceuticals prices $175M public offering

* Amylyx Pharmaceuticals (NASDAQ:AMLX [https://seekingalpha.com/symbol/AMLX]) priced [https://seekingalpha.com/pr/20227278-amylyx-pharmaceuticals-announces-pricing-of-175-million-underwritten-public-offering-of] an underwritten public of... Full story

Yahoo Finance • last month

Amylyx drops clinical program for neuro disorder after trial readout

[Isolated Document Red X Error Cancelled] Anton Zacon/iStock via Getty Images * Amylyx Pharmaceuticals (NASDAQ:AMLX [https://seekingalpha.com/symbol/AMLX]) announced on Wednesday that it has decided to discontinue a clinical program tar... Full story

Yahoo Finance • last month

Amylyx Pharmaceuticals discontinues ORION program for AMX0035 in PSP

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), currently trading at $9.16 and showing a remarkable 330% return over the past year, announced Wednesday that it is discontinuing the ORION program evaluating AMX0035 in adults with progressive su... Full story

Yahoo Finance • 2 months ago

Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline

Earnings Call Insights: Amylyx Pharmaceuticals (AMLX) Q2 2025 MANAGEMENT VIEW * Co-CEO Justin B. Klee highlighted "meaningful progress across our clinical programs" in the first half of 2025, emphasizing Avexitide as the lead asset, wh... Full story

Yahoo Finance • 2 months ago

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted

AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX [https://www.chartmill.com/stock/quote/AMLX]) REPORTS Q2 2025 EARNINGS: EPS IN LINE, MARKET REACTION MUTED Amylyx Pharmaceuticals Inc released its second-quarter 2025 financial results, posting a ne... Full story

Yahoo Finance • 2 months ago

Amylyx Pharmaceuticals Q2 2025 Earnings Preview

* Amylyx Pharmaceuticals (NASDAQ:AMLX [https://seekingalpha.com/symbol/AMLX]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. The consensus EPS Estimate is -$0.45 [https://seekingalpha.com/symbo... Full story

Yahoo Finance • 3 months ago

Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and Phase 2b clinical trials of avexitide for... Full story

Yahoo Finance • 3 months ago

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Amylyx Pharmaceuticals,... Full story

Yahoo Finance • 3 months ago

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story

Yahoo Finance • 4 months ago

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to sha... Full story

Yahoo Finance • 4 months ago

Amylyx gets FDA fast track status for ALS treatment

[ALS acronym on colorful wooden cubes] chrupka/iStock via Getty Images Amylyx Pharmaceuticals (NASDAQ:AMLX [https://seekingalpha.com/symbol/AMLX]) said on Tuesday that the U.S. FDA has granted fast track status to its antisense RNA, AMX01... Full story

Yahoo Finance • 6 months ago

Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds?

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stands against other biotech penny stocks. P... Full story

Yahoo Finance • 2 years ago

15 Small-Cap Stocks with High Potential

In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story

Yahoo Finance • 2 years ago

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • 2 years ago

14 Best Depressed Stocks To Buy Now

In this article, we will take a look at the 14 best depressed stocks to buy now. To see more such companies, go directly to 5 Best Depressed Stocks To Buy Now. Legendary value investor Howard Marks started writing memos to investors decad... Full story

Yahoo Finance • 2 years ago

Analysts Are Cutting Price Targets of These 10 Stocks

In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Analysts Are Cutting Price Targets of These 5 Stocks. During the June me... Full story

Yahoo Finance • 4 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLX

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX). Such investors are advised to contact Robert S. Willoug... Full story